The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Jan 2008
Randomized Controlled TrialIntranasal noninhaled carbon dioxide for the symptomatic treatment of seasonal allergic rhinitis.
Noninhaled intranasal carbon dioxide (CO2) has been shown to be effective in the abortive treatment of migraine headache. Migraine headache is associated with trigeminal neuronal activation and release of calcitonin gene-related peptide, events also implicated in allergic rhinitis. Intranasal CO2 might inhibit trigeminal neuronal activation and suppress the release of calcitonin gene-related peptide. ⋯ Two 60-second intranasal CO2 treatments resulted in rapid (10 minutes) and sustained (24 hours) relief of seasonal allergic rhinitis symptoms.